CO-WESTERN-UNION-COMPANY
Western Union (NYSE: WU), a leader in cross-border, cross-currency money movement, and Techstars, the global platform for investment and innovation, today announced the launch of its second class of the Techstars & Western Union Accelerator . From machine learning and artificial intelligence, to cloud services, digital banking and advanced analytics, the common thread across the portfolio of 10 companies is their commitment to leveraging technology and innovation to create greater access to global and local economies, through inclusive finance.
The 2020 Accelerator companies are led by founders originating from across the world, including the Philippines, Egypt, Gambia, Hong Kong, Indonesia, India, Israel, Nigeria, Singapore, Spain, South Africa and the United States. They share Western Union’s commitment to inclusive innovation by developing products and services that accelerate access for a more equitable global financial system.
The concept of financial access served as the North Star throughout the 2020 Accelerator selection process, as program leaders contemplated the question: In the face of a global health crisis, which companies are best positioned to accelerate and expand financial access in a post-COVID world?
The startup founders will participate in an intensive 13-week virtual program during which they will focus on growing and evolving their companies with the mentorship, entrepreneurial expertise, business strategy and marketing guidance of fintech subject matter experts in a range of areas, including compliance, mobile wallets and settlement.
“The Western Union team is tremendously impressed with this diverse group of founders and entrepreneurs who are actively addressing challenges across the financial services ecosystem,” said Western Union President of Product and Platform, Shelly Swanback. “I am confident that the breadth of perspective, experience and technologies represented in this year’s portfolio will drive us to be even more disruptive as we endeavor to develop more inclusive financial services and payment technologies in a rapidly changing global economy.”
Swanback added, “I am especially proud of the fact that many of the companies in the accelerator are led by founders from many different countries, which nicely reflects the global diversity of our employee, customer and partner base. A global lens is critical as we look to create opportunities for billions of people to access the latest innovations in finance, innovate opportunities for businesses and customers, and help close the growing inequality gap.”
According to the New American Economy, a U.S.-based bipartisan research and advocacy organization focused on federal, state, and local immigration policies, in 2019 approximately 45% of Fortune 500 companies were founded by immigrants or their children.
“We are proud to announce the companies selected to participate in the 2020 Techstars & Western Union Accelerator,” said Ethan Austin , Managing Director of the Techstars Western Union Accelerator. “Each of these companies is tackling systemic industry obstacles with innovative and original solutions using leading edge technologies. We are excited to support their continued growth over the next 13 weeks of our program and beyond.”
The 2020 Techstars & Western Union Accelerator will culminate with a Demo Day on Oct. 8, where startup founders will pitch their products and services to potential investors. This year, the program has shifted from an in-person to virtual program due to the impact of the COVID-19 pandemic.
Since 2006, Techstars has worked with more than 2,000 startups, forging deep and meaningful relationships between young startup companies and global corporations. The competitive selection process for the Techstars & Western Union Accelerator began in early 2020 with hundreds of entrepreneurs vying for one of 10 coveted spots.
Techstars and Western Union extend a hearty congratulations and a warm welcome to the 2020 Techstars & Western Union Accelerator companies.
2020 Techstars Western Union Accelerator Roster
|
||||
AidBanc Little Rock, AR | USA and LA
AidBanc empowers NGOs with digital banking and spend management tools to seamlessly disburse aid in an increasingly cashless world.
|
Plentina San Francisco, CA | USA Cloud services provide alternative credit scoring and lending for global financial inclusion. |
|||
Gig Wage Dallas, TX | USA Gig Wage is a payments platform specializing in independent contractors. Their technology makes it simple, fast and easy to pay, manage, and support contractors. |
Rise Capital Lagos, Nigeria A technology-driven finance company connecting everyday Africans with the best dollar-denominated investment opportunities around the world. |
|||
Heights Labs New York, NY | USA AI and network analytics platform for risk, fraud, compliance, and AML/CFT to mitigate risks and threats across the compliance, intelligence, and national security landscape. |
Robbie AI Boston, MA | USA Facial recognition technology through real-time streaming in natural settings. |
|||
Line San Francisco, CA | USA
AI-powered technology helps qualified and banked individuals establish credit and access to affordable financial services.
|
Vested Finance Berkeley, CA | USA Investment advisory platform promoting sustainable wealth creation by empowering local Indian investors to go global. |
|||
Logicluster San Francisco, CA | USA An Artificial Intelligence powered pricing engine to enable businesses to grow revenue through optimized pricing. |
Yunit Oakland, CA | USA Allows users to save money with their friends. |
|||
WU-G
About Techstars
Techstars is a global platform for investment and innovation. Techstars founders connect with other entrepreneurs, experts, mentors, alumni, investors, community leaders, and corporations to grow their companies. Techstars operates three divisions: Techstars Mentorship-Driven Accelerator Programs, Techstars Corporate Innovation Partnerships, and Techstars Community. Techstars accelerator portfolio includes more than 2,200 companies with a market cap of more than $26 billion. www.techstars.com
About Western Union
The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of March 31, 2020, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts.
Additionally, westernunion.com , our fastest growing channel in 2019, is available in over 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends, and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005456/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom